论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Wang X, Hua Y, Xu G, Deng S, Yang D, Gao X
Received 5 October 2018
Accepted for publication 7 January 2019
Published 15 April 2019 Volume 2019:14 Pages 2637—2653
DOI https://doi.org/10.2147/IJN.S189871
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Dr Lei Yang
Background: For the
past few years, gene-therapy has recently shown considerable clinical benefit
in cancer therapy, and the applications of gene therapies in cancer treatments
continue to increase perennially. EZH2, an ideal candidate for tumor gene
therapy, plays an important role in the tumorigenesis.
Methods: In this
study, we developed a novel gene delivery system with a self-assembly method by
Methoxy polyethylene glycol-polycaprolactone (MPEG-PCL) and DOTAP(DMC). And
EZH2si-DMC was used to research anti-glioma both in vitro and in vivo.
Results: DMC with
zeta-potential value of 36.7 mV and size of 35.6 nm showed good performance in
the delivery siRNA to glioma cell in vitro with high 98% transfection
efficiency. EZH2si-DMC showed good anti-glioma effect in vitro through inducing
cell apoptosis and inhibiting cell growth. What’s more, treatment of
tumor-bearing mice with DMC-EZH2si complex had significantly inhibited tumor
growth at the subcutaneous model in vivo by inhibiting EZH2 protein expression,
promoting apoptosis and reducing proliferation.
Conclusion: The EZH2
siRNA and DMC complex may be used to treat the glioma in clinical as a new
drug.
Keywords: glioma,
gene therapy, EZH2, MPEG-PCL, DOTAP, tumorigenesis